Journal article

The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition

MJ Wall, G Wigmore, J Lopatář, BG Frenguelli, N Dale

Neuropharmacology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2008

Abstract

Understanding the mechanisms and properties of purinergic signalling would be greatly assisted by the discovery of subtype selective and potent inhibitors of the NTPDase enzymes, which metabolise nucleotides such as ATP and ADP in the extracellular space. Currently ARL 67156 is the best available NTPDase inhibitor, but its relatively poor efficacy means that negative results are difficult to interpret. POM-1 (sodium polyoxotungstate) is a novel NTPDase inhibitor, which has shown promising results with the inhibition of recombinant NTPDases 1, 2 and 3. We have tested the effectiveness and physiological effects of POM-1 with cerebellar and hippocampal slices. Using the malachite green phosphat..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Medical Research Council


Funding Acknowledgements

We would like to thank Professor Christa Willer for the POM-1 sample and for comments on early drafts of the manuscript. We are also grateful to Dr. Rob Eason and Stephanie zur Nedden for assistance with the HPLC experiments. Jan Lopatar is funded by Epilepsy Research UK.